Abstracts Archive - Page 302 of 2607 - ACR Meeting Abstracts

Abstract Number: 1686 • ACR Convergence 2024
Urine Proteomics in Class II Lupus Nephritis Reveals Immune Activation and Pro-Fibrotic Signatures
Jasmine Shwetar¹, Jill Buyon², Michelle Petri³, Kelly Ruggles⁴ and Andrea Fava⁵, ¹New York School of Medicine, Ann Arbor, MI, ²NYU Grossman School of Medicine, New York, NY, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴NYU Grossman School of Medicine, Brooklyn, NY, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) is a pathologically diverse autoimmune disease that can lead to end-stage kidney disease and mortality. Although Class II LN is considered…
Abstract Number: 1718 • ACR Convergence 2024
Randomization to Holding versus Continuing (JAKi, IL17) and Autoimmune Patient Responses to COVID-19 Boosters: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study
Amy Mudano¹, Gary Cutter², Emily Holladay³, Kevin Winthrop⁴, Ted Mikuls⁵, Geoffrey Thiele⁵, Mark Law⁵, Monique Bastidas⁶, Mike Zikry⁶, Kelly Chun⁶, Michael George⁷, Jayashree Sinha⁸, Naiara Alvarez⁹, John Tesser¹⁰ and Jeffrey Curtis¹¹, and COVER Site Principal Investigator Group, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Edmond, OK, ⁴School of Medicine, Oregon Health and Science University, Portland, OR, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Labcorp, Calabasas, CA, ⁷University of Pennsylvania, Philadelphia, PA, ⁸self employed, Clovis, NM, ⁹Integrative Rheumatology of South Texas, McAllen, TX, ¹⁰Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹¹University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Best practice for the use of immunosuppression to optimize vaccine response remains uncertain. We conducted the Covid VaccinE Response (COVER) trial, a multicenter, randomized…
Abstract Number: 1733 • ACR Convergence 2024
Safety and Efficacy of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Saira Sheikh¹, Tahseen Mozaffar², Vimal Derebail¹, Natalie Grover¹, Jonathan Hogan³, Courtney Little³, Yvonne White³, Claire Miller³, Rebecca Estremera³, Jenell Volkov³, Daniel Nunez³, Jason Stadanlick³, Mallorie Werner³, Zachary Vorndran³, Alexandra Ellis³, Jazmean Williams³, Justin Cicarelli³, Quynh Lam³, thomas Furmanak³, Chris Schmitt³, Fatemeh Nezhad³, Dan Thompson³, Samik Basu³ and David Chang³, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²University of California, Irvine, Irvine, CA, ³Cabaletta Bio, Philadelphia, PA
Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…
Abstract Number: 1628 • ACR Convergence 2024
Tocilizumab for Giant Cell Arteritis in Japan over 2 Years: A Multicenter Retrospective Study
Nobuhiro Oda¹, Sho Fukui², Toshihiro Yamaguchi³, Fumika Nagase⁴, Takanori Ito⁵, Mitsuru Watanabe⁵, Yoichiro Haji⁴, Yasuhiro Suyama⁶, Atsushi Nomura⁷, Eishi Uechi⁸, Masei Suda³, Naoho Takizawa⁴, Ryo Rokutanda⁹ and Hiromichi Tamaki¹⁰, ¹Kameda medical center, Department of Rheumatology, Higashi-cho, Kamogawa, Japan, ²Brigham and Women's Hospital, Brookline, MA, ³Suwa Central Hospital, Department of Rheumatology, Nagano, Japan, ⁴Chubu Rosai Hospital, Department of Rheumatology, Aichi, Japan, ⁵Daido Hospital, Department of Rheumatology, Aichi, Japan, ⁶NTT Medical Center Tokyo, Department of Rheumatology, Tokyo, Japan, ⁷Ushiku Aiwa General Hospital, Department of Rheumatology, Ibaraki, Japan, ⁸Yuai Medical Center, Department of Rheumatology, Okinawa, Japan, ⁹Kameda medical center, Department of Rheumatology, Chiba, Japan, ¹⁰St. Luke’s International Hospital, Immuno-Rheumatology Center, Tokyo, Japan
Background/Purpose: The GiACTA trial, a phase III global trial of tocilizumab (TCZ) for giant cell arteritis (GCA), did not involve Japanese patients, and real-world data…
Abstract Number: 1697 • ACR Convergence 2024
Results of a One Year Randomized Double-Blind Placebo-Controlled Trial with Methotrexate 25mg Per Week for Recently Diagnosed PolyMyalgia Rheumatica
Thomas Bolhuis¹, Noortje Kooijman¹, Diane Marsman¹, Gijs Snijders², Alfons den Broeder³, Nathan den Broeder⁴ and Aatke Van der maas⁵, ¹Department of Rheumatology, Sint Maartenskliniek, Ubbergen, The Netherlands, Ubbergen, Netherlands, ²Department of Rheumatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands, Gelre, Netherlands, ³Sint Maartenskliniek, Ubbergen, Netherlands, ⁴Sint Maartenskliniek, Ubbergen, Gelderland, Netherlands, ⁵St Maartenskliniek, Ubbergen, Netherlands
Background/Purpose: The most effective treatment for Polymyalgia rheumatica (PMR) are glucocorticoids (GC), but these are associated with toxicity. Three randomized controlled trials (RCTs) suggest methotrexate…
Abstract Number: 1614 • ACR Convergence 2024
Mortality in Patients with Giant Cell Arteritis in Spain: Results from the ARTESER Registry
Juan Molina-Collada¹, Marta Domínguez-Álvaro², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maite Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael Gonzalez⁷, Julio Sánchez-Martín⁸, Javier Narvaez-García⁹, Joan Calvet¹⁰, Ivette Casafont-Solé¹¹, José A Román Ivorra¹², Selene Labrada-Arrabal¹³, Margarida Vasques Rocha:¹⁴, Carlota L Iñiguez:¹⁵, Maria Sagrario Bustabad Reyes¹⁶, Cristina Campos-Fernández¹⁷, María Alcalde Villar:¹⁸, Antonio Juan-Mas¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Ourense, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Hospital Universitario Donosti. Donostia, Spain, Donosti, Spain, ⁷Complejo Asistencial Universitario de Leon, León, Spain, ⁸Hospital Universitario 12 de Octubre, Madrid, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA) (UAB), 08208 Sabadell, Spain, Barcelona, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, Barcelona, Spain, ¹²Hospital Universitari i Politècnic La Fe, Valencia, Spain, Valencia, Spain, ¹³Hospital del Mar, Barcelona, Spain, ¹⁴Hospital Universitario Araba, Vitoria, Spain, ¹⁵Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁶Hospital Universitario de Canarias, La Laguna - Tenerife, Spain, ¹⁷Consorci Hospital General Universitari de València, Comunitat Valenciana, Spain, Valencia, Spain, ¹⁸Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain, ¹⁹Hospital Universitari Son Llàtzer, Mallorca, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: The question of survival in epidemiologic studies on giant cell arteritis (GCA) remains unclear to date, with notable heterogeneity in both the mortality rate…
Abstract Number: 1505 • ACR Convergence 2024
Incidence of Cardiovascular and Venous Thromboembolic Events in Four Autoantibody-defined Systemic Lupus Erythematosus Clusters
Sara Ferrigno¹, Elizabeth Arkema², Lina Marcela Diaz-Gallo³, Iva Gunnarsson⁴, Agneta Zickert⁴ and Elisabet Svenungsson⁵, ¹Department of Systems' Medicine, University of Rome Tor Vergata, Rome, Italy, ²Department of Medicine Solna, Clinical Epidemiology Division, Stockholm, Sweden, ³Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) patients have higher cardiovascular (CV) risk compared to the general population, with a standardized CV mortality rate of 2-3 and…
Abstract Number: 1729 • ACR Convergence 2024
Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Karolina Lungova¹, Katherine Sherman², Mahum Mirza¹, Rohan Mehta¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect immunocompromised patients. PJP prophylaxis has been recommended for some autoimmune diseases but not others.…
Abstract Number: 1625 • ACR Convergence 2024
Impacts of a Fast-Track Referral Clinic on Health Care Utilization, Delays and Complications in Patients with Giant Cell Arteritis
Alae Dhahbi¹, Stephanie Ducharme-Benard², Samer Hussein³, Rosalie-Sélène Meunier², Hussein Baalbaki², Carolyn Ross⁴ and Jean-Paul Makhzoum⁴, ¹Laval University, Quebec, QC, Canada, ²Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ³Vasculitis Clinic, Hopital du Sacre-Coeur de Montreal, Sherbrooke, Canada, ⁴Vasculitis Clinic, Canadian Network for Research on Vasculitides, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada
Background/Purpose: Giant cell arteritis (GCA) is both a medical emergency and diagnostic challenge. Up to 45% of patients may require emergency department (ED) visits and/or…
Abstract Number: 1731 • ACR Convergence 2024
Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial
hector Chinoy¹, Ashma Krishan¹, Yvonne Sylvestre¹, James Lilleker², Patrick Gordon³, Sarah Tansley⁴, Athiveeraramapandian Prabu⁵, Aamir Aslam⁶, Andrew Snedden⁷ and Janine Lamb⁸, ¹The University of Manchester, Manchester, United Kingdom, ²Northern Care Alliance NHS Trust, Salford, United Kingdom, ³nhs, London, United Kingdom, ⁴University of Bath, Bath, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ⁸University of Manchester, UK, Manchester, United Kingdom
Background/Purpose: The aim of the study was to assess the effects of baricitinib, a JAK1/2 inhibitor, following 24 weeks of active treatment on disease activity…
Abstract Number: 1699 • ACR Convergence 2024
Anakinra in Giant Cell Arteritis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Hubert de Boysson¹, Kim Ly², Loik Geffray³, Thomas Quemeneur⁴, Eric Liozon⁵, Holy Bezanahary⁵, Noemie Le Gouellec⁴, Alexandra Audemard⁶, Samuel Deshayes⁷, Jonathan Boutemy⁸, Gwénola Maigné⁸, Nicolas Martin Silva⁸, Jean-Jacques Parienti⁸ and Achille Aouba⁷, ¹Caen university Hospital, Caen, France, ²CHU Limoges, limo, France, ³CH Lisieux, Lisieux, France, ⁴CH Valenciennes, Valenciennes, France, ⁵CHU Limoges, Limoges, France, ⁶Tours, Tours, France, ⁷Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, ⁸CHU Caen, Caen, France
Background/Purpose: A previous retrospective series reported the efficacy and tolerance of anakinra (ANK) in giant cell arteritis (GCA) and called for further validation in a…
Abstract Number: 1634 • ACR Convergence 2024
A Lexicon of Signs and Symptoms of Giant Cell Arteritis: An International Expert Consensus
Medha Soowamber¹, Milena Bond², Carol Langford³, Zahi Touma¹, Catalina Sanchez Alvarez⁴, Andy Abril⁵, Sibel Aydin⁶, FRANK HARTMUT DR. BUTTGEREIT⁷, Dario Camellino⁸, Maria Cid⁹, Peter Grayson¹⁰, Bernhard Hellmich¹¹, William Lichliter¹², Tanaz Kermani¹³, Nader Khalidi¹⁴, Sarah Mackie¹⁵, Eric Matteson¹⁶, Mehrdad Maz¹⁷, Peter Merkel¹⁸, Paul Monach¹⁹, Lorna Neill²⁰, Cristina Ponte²¹, Carlo Salvarani²², Wolfgang Schmidt²³, Peter Villiger²⁴, Kenneth Warrington²⁵, Madeline Whitlock²⁶, Sofia Ramiro²⁷ and Christian Dejaco²⁸, ¹University of Toronto, Toronto, ON, Canada, ²Unit of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsus Medical University, Bruneck, Italy, ³Cleveland Clinic, Moreland Hills, OH, ⁴University of Florida, Gainesville, FL, ⁵Mayo Clinic, Ponte Vedra Beach, FL, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸La Colletta hospital, Arenzano, Italy, ⁹Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain, ¹⁰National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ¹¹Medius Kliniken, Kirchheim unter Teck, Germany, ¹²patient, Vienna, Austria, ¹³University of California Los Angeles, Santa Monica, CA, ¹⁴McMaster University, Hamilton, ON, Canada, ¹⁵University of Leeds, Leeds, United Kingdom, ¹⁶Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁷The University of Kansas Medical Center, Kansas City, KS, ¹⁸University of Pennsylvania, Philadelphia, PA, ¹⁹VA Boston Healthcare System, Boston, MA, ²⁰Patient Charity Polymyalgia Rheumatica and Giant Cell Arteritis Scotland, Nethy Bridge, United Kingdom, ²¹Unidade Local de Saúde Santa Maria, Serviço de Reumatologia e Doenças Ósseas Metabólicas, Lisboa, Portugal., Lisbon, Portugal, ²²Azienda USL-IRCCS di Reggio Emilia and University of Modena and Reggio Emilia, Reggio Emilia, Italy, Reggio Emilia, Italy, ²³Immanuel Krankenhaus Berlin, Berlin, Germany, ²⁴Medical Center Monbijou, Bern, Switzerland, ²⁵Mayo Clinic, Rochester, MN, ²⁶Southend University Hospital, Southend, United Kingdom, ²⁷Leiden University Medical Center, Bunde, Netherlands, ²⁸Azienda Sanitaria Alto Adige, Brunico, Italy
Background/Purpose: The lack of standardized definitions and descriptors for clinical manifestations of giant cell arteritis (GCA) leads to variable interpretations of findings in clinical practice…
Abstract Number: 1507 • ACR Convergence 2024
To Develop a Method for Estimating Interferon Signatures in SLE from Routine Clinical Laboratory Tests
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai¹ and Moe Tokunaga³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc., Tokyo, ³Japanese Red Cross Okayama Hospital, Okayama
Background/Purpose: IFN signatures are known to play an important role in the pathogenesis of systemic autoimmune diseases such as SLE. Recently, therapeutic agents targeting IFN…
Abstract Number: 0198 • ACR Convergence 2024
COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study
Carol Hitchon¹, Carole Taylor¹, Charles N Bernstein¹, Christine Peschken¹, J. Antonio Avina-Zubieta², Sasha Bernatsky³, Gil Kaplan⁴, Diane Lacaille², Jessica Widdifeild⁵ and RuthAnn Marrie¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: People with immune mediated inflammatory diseases (IMIDs) are at greater risk of severe Coronavirus disease (COVID-19). Vaccination reduces COVID-19 severity however, vaccine uptake may…
Abstract Number: 2676 • ACR Convergence 2024
Timeframe for Initiating Methotrexate and Vaccine Response Against Pneumococcus in Rheumatoid Arthritis: The VACIMRA Study
Jacques MOREL¹, Emmanuelle Dernis², christian roux³, Christophe Richez⁴, OLIVIER BROCQ⁵, Bruno Fautrel⁶, Carine SALLIOT⁷, Olivier Vittecoq⁸, Xavier Mariette⁹, Frédéric LIOTE¹⁰, Slim Lassoued¹¹, Cécile Gaujoux-Viala¹², Arnaud Constantin¹³, MArtin Soubrier¹⁴, Valerie Devauchelle¹⁵, Vincent Goeb¹⁶, Jacques-Eric Gottenberg¹⁷, Hubert Marotte¹⁸, Annouc Rémy Moulard¹, Corinne Merle de Boever¹, Héléna Huguet¹, Odile Launay¹⁹, Florence Galtier¹ and Marie Christine Picot¹, and F-CRIN networks iREIVAC and CRI-IMMIDIATE, ¹CHU and University of Montpellier, Montpellier, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³rheumatology department, university Cote d'Azur, nice, France, ⁴Université de Bordeaux, Bordeaux, France, ⁵Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁶INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ⁷CHU and University of Orléans, Orléans, France, ⁸CHU and University of Rouen, Rouen, France, ⁹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁰CHU and University of Paris Nord, Paris, France, ¹¹CH of Cahors, Cahors, France, ¹²CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ¹³Hôpitaux de Toulouse, Toulouse, France, ¹⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁵UBO, Brest, France, ¹⁶CHu and University of Amiens, Ameins, France, ¹⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹⁸Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ¹⁹Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France
Background/Purpose: Pneumococcal vaccination is recommended for patients with chronic inflammatory rheumatism treated with immunosuppressants. Methotrexate (MTX) is the first-line treatment used in rheumatoid arthritis (RA),…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].